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Abstract. In recent years, growth hormone (GH) deficiency in adults has been 
recognized as a specific clinical syndrome. An almost twofold increase in 
cardiovascular mortality, premature atherosclerosis, unfavourable lipoprotein 
patterns, abnormal body composition and impaired psychological well-being have 
been linked with this syndrome. 
The aim of this study was to investigate adult GH deficiency in terms of 
metabolic and hemostatic factors associated with cardiovascular disease. 
Furthermore, the effects of long-term treatment with GH on hemostasis and the 
effects of G H on neurotransmitters and GH-dependent factors in the cerebrospinal 
fluid (CSF) were studied. We also compared the metabolic effects of different GH 
administration modes. 
Insulin sensitivity was assessed using the hyperinsulinemic euglycemic clamp 
technique. Glucose infusion rate in GH-deficient subjects was less than half compared 
with controls (pcO.OOl), thus indicating that GH-deficient adults are insulin-resistant. 
Despite this, a normal fasting insulin level was found. Patients had similar or even 
lower fasting blood glucose levels (p<0.05) and lower fasting free fatty acid levels 
compared with controls (p<0.01). The waist over hip circumference ratio (p<0.001), 
plasminogen activator inhibitor (PAI-1) activity (p<0.05), fibrinogen (pcO.OOl) and 
serum triglyceride levels (p<0.05) were higher in the patients. 
After 18-24 months of GH treatment, PAI-1 activity, PAI-1 antigen and tissue 
plasminogen activator (t-PA) antigen decreased (p<0.05). The rapid plasmin inhibitor, 
a2-antiplasmin, (p<0.05) and the coagulation inhibitor, protein C (p<0.05), decreased. 
Blood glucose levels did not differ after two years of G H treatment, but fasting 
insulin levels (pcO.Ol) and lean body mass (p<0.001) increased . 
In an administration study, serum insulin-like growth factor 1 (IGF-1) and IGF 
binding protein-3 (IGFBP-3) levels increased to a higher degree during two weeks of 
subcutaneous continuous infusion of GH compared with daily subcutaneous 
injections in the evening (p<0.01). Fasting free fatty acid levels only increased during 
treatment with daily injections of GH (p<0.01). The fasting blood glucose level and an 
oral glucose tolerance test indicated more impaired glucose tolerance after daily 
injections of GH compared with continuous infusion. 
In another study, the mean CSF GH concentration increased tenfold compared 
with baseline (p=0.002) after one month of GH treatment. CSF IGF-1 (p=0.005), CSF 
IGFBP-3 concentrations (p=0.002) and CSF ß-endorphin immunoreactivity also 
increased (p=0.002) while dopamine metabolite homovanillic acid (p=0.02) and 
vasoactive intestinal peptide (p=0.03) decreased. 
In conclusion, insulin resistance and abnormalities in fibrinolysis and 
coagulation can be added to the syndrome of G H deficiency in adults. During GH 
treatment, favourable changes in body composition and the fibrinolytic system were 
noted. Continuous infusion of GH resulted in higher serum IGF-1 and IGFBP-3 levels 
compared with daily injections. Moreover, our study indicates that GH passes the 
blood-CSF barrier and that GH affects the CSF levels of both IGF-1 and 
neurotransmitters. Neuroendocrine mechanisms might be involved in the 
improvement in psychological well-being observed during GH treatment. 
Key words: Growth hormone, growth hormone deficiency, insulin-like growth 
factor 1, insulin resistance, free fatty acids, fibrinogen, plasminogen activator 
inhibitor-1, coagulation, fibrinolysis, waist over hip circumference ratio, cerebrospinal 
fluid, neuropeptides ISBN 91-628-2024-9 
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1. Introduction 
Historical background 
Although it has been recognized for 
many years that growth hormone (GH) is 
also secreted in adult life, it has been 
claimed that GH exerts no effects in adults 
(205). However, early anecdotal evidence 
has hinted at the metabolic effects of GH in 
adults. In 1962, increased vitality following 
GH therapy in one adult patient with 
panhypopituitarism was reported (167). 
Furthermore, in his thesis in 1963, Thomas 
Falkheden described the pathophysiological 
effects of hypophysec tomy in adult patients 
who were hypophysectomized because of 
metastatic mammary carcinoma, diabetes 
mellitus or acromegaly. Despite con­
ventional hormone replacement therapy, 
there was a d ecrease in basal metabolism, 
renal function, blood volume and cardiac 
performance within one month post­
operatively. It was postulated that the 
observed changes were due to the abolition 
of o r reduction in GH secretion caused by 
the hypophysectomy (56). 
Since GH deficiency (GHD) is an 
early event in the development of 
hypopituitarism, most patients with GHD 
acquired in adult life also have deficiencies 
in the regulation of the thyroid gland, 
adrenal cortex and gonads. Until recently, 
conventional hormone replacement 
treatment for these patients has been L-
thyroxine, corticosteroids and sex 
hormones. 
GHD in adults 
In recent years, the clinical features of 
GHD in adults have been defined. In GH-
deficient adults, characteristic changes in 
body composition with decreased LBM, 
reduced total body water, mainly 
extracellular, and increased body fat have 
been consistent findings (40,95,179,185). In 
addition, a decrease in bone mineral 
content (106,181), a reduction in glomerular 
filtration rate, renal plasma flow (95), 
sweating (162), thermoregulation (93), 
maximum oxygen uptake during exercise 
(36), cardiac function (7, 140), isometric 
muscle strength and exercise capacity have 
been demonstrated (100). Moreover, poor 
quality of life in terms of energy, social 
isolation and emotional distress has been 
recorded in GH-deficient adults (18, 133 , 
182). 
An association with GHD and 
premature arteriosclerosis has been 
suggested by the observation of an almost 
twofold increase in cardiovascular 
mortality found in a re trospective study of 
333 patients with hypopituitarism (178) and 
by the increased number of ath eromatous 
plaques in the femoral and carotid arteries 
of patients with hypopituitarism (131). 
Increased concentrations of serum 
triglyceride, serum total cholesterol and 
LDL cholesterol, as well as decreased serum 
HDL cholesterol concentration, have been 
reported in GH-deficient adults (38, 122, 
131,139,180). In one study by Rosén et al., 
the prevalence of treated hyp ertension was 
higher, whereas the prevalence of smoking 
was lower in the GH-deficient group 
compared with controls (180). The 
dyslipidemia may, at least in part, explain 
the increased prevalence of cardiovascular 
disease in GH-deficient adults. However, 
there are several other factors known to be 
associated with cardiovascular disease 
which have not been sufficiently evaluated 
in GH-deficient adults. These factors 
include fibrinogen levels, PAI-1 activity and 
insulin sensitivity. 
From the late 1950s, GH-deficient 
children were treated with GH prepared 
from human cadaveric pituitaries. Due to 
the limited supply of GH, clinical trial s of 
GH treatment in hypopituitary adults were 
not possible until biosynthetic human GH 
produced by recombinant DNA techniques 
became available in the mid-1980s. 
Replacement therapy with GH in GH-
deficient adults alters body composition 
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through its lipolytic, protein anabolic and 
anti-natriuretic actions. An increase in lean 
body mass, a decrease in fat mass with a 
redistrubution of fat from visceral to 
peripheral depots, as well as an increase in 
extracellular water volume, have been 
consistent findings in many studies (12,16, 
43, 100, 185). GH replacement therapy 
increases the rate of bone turnover (193, 
207) and increases both bone mineral 
density and bone mineral content (43, 89). 
Furthermore, a decrease in total serum 
cholesterol (87, 185) and LDL cholesterol 
levels, as well as an increase in HDL 
cholesterol levels, have been observed (87). 
In addition, GH replacement therapy in 
GH-deficient adults is associated with 
increased exercise capacity (95, 100, 207), 
improved cardiac function (37) and 
improved quality of life, mainly in terms of 
energy level and mood (133). However, the 
mechanisms underlying these beneficial 
effects on psychological well-being are 
unknown. 
Coagulation and fibrinolysis 
Hemostasis depends upon complex 
interactions between plasma coagulation, 
fibrinolysis, blood cells and vessel walls, as 
well as blood viscosity and blood flow. 
Fibrinogen (coagulation factor I) is a 
glycoprotein which is mainly produced in 
the liver. The cleavage of fibrinogen to 
fibrin by thrombin is the final step in the 
coagulation process. Fibrin and platelets 
then combine to form a clot. Previous 
population-based studies have shown that 
fibrinogen is an independent risk factor for 
stroke as well as myocardial infarction, at 
least as important as blood lipids and blood 
pressure (136, 208). Fibrinogen is also an 
acute-phase protein and the concentration 
increases as a result of inflammation, 
infection, injury and stress. In fibrinolysis, 
fibrin is proteolytically degraded in order to 
prevent thrombus formation. It is generally 
accepted that fibrinolytic activity influences 
the growth, size and dissolution of the 
thrombus. The fibrinolytic process is 
schematically outlined in Fig. 1. 
t-PA converts plasminogen to the key 
enzyme plasmin, whereafter the degra­
dation of th e fibrin network can take place. 
PAI-1, the fast-acting t-PA inhibitor, is the 
major regulator of fibrinolytic activity in 
plasma. The mature PAI-1 molecule is a 379 
amino acid long single-chain glycoprotein 
which is mainly synthesized in endothelial 
cells, vascular smooth-muscle cells, 
hepatocytes and platelets (109,190,192). In 
the circulation, PAI-1 antigen occurs in 
three main forms: as an active molecule, as 
a t-PA/PAI-1 complex and in a latent, 
inactive form. PAI-1 exerts its inhibitory 
action by forming an inactive complex with 
O PAI-1 
Q a2-antiplasmin 
t-PA 
Fibrinogen FDP Fibrin 
Plasminogen Plasmin 
Fig. 1. Diagram of the fibrinolytic process. FDP=Fibrin degradation products. 
© = inhibitory effect. 
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t-PA which is then cleared through the liver. 
The mechanisms underlying the changes in 
PAI-1 activity in plasma are largely 
unknown. However, PAI-1 synthesis in 
vitro is stimulated by a variety of factors 
including endothelial damage, inflam­
mation, endotoxin, thrombin, transforming 
growth factor ß, basic fibroblast growth 
factor, epidermal growth factor and 
hormones such as glucocorticoids and 
insulin (109, 190, 192). Increased PAI-1 
activity acts in a thrombogenic direction. 
Elevated PAI-1 activity has been associated 
with coronary artery disease (92, 158), 
increased risk of myocardial infarction in 
young patients (65), recurrent myocardial 
infarction (66) and deep vein thrombosis 
(153). In addition, high PAI-1 activity has 
been found in individuals with abdominal 
obesity, hypertension and type II d iabetes 
(67, 83, 91, 114, 115, 144, 204). A positive 
correlation has been found between PAI-1 
activity and VLDL triglyceride concen­
tration, as well as with insulin concen­
tration, BMI and WHR (10, 29,52, 62, 67, 83, 
114, 115, 144, 204). Other factors in hemo-
stasis, such as factor VII and t-PA antigen, 
have also been associated with an increased 
risk of cardiovascular disease (84, 108, 136, 
173). 
In vivo studies involving GH 
administration for a few hours up to a week 
have suggested that GH plays a role in the 
regulation of von Willebrand factor which 
circulates in a complex with factor VIII (21, 
80, 189). In contrast, no effect was seen on 
fibrinogen, t-PA antigen, factor VIII or von 
Willebrand factor levels during four 
months of GH treatment in adults with 
GHD (98). 
Effects of GH on glucose 
homeostasis 
GH exerts both insulin-like and 
insulin-antagonistic effects, although the 
physiological significance of the former is 
uncertain. A transient insulin-like effect is 
observed during the first three hours after 
GH administration (1, 17, 128, 201). The 
insulin-antagonistic or diabetogenic effect 
on glucose metabolism is obvious in 
acromegaly, a condition with chronic GH 
excess due to a GH^producing pituitary 
adenoma (39, 68). When high doses of GH 
are administered to normals, the insulin-
antagonistic effect is observed after a lag of 
three to four hours (166, 183). In sustained, 
more physiological doses, GH appears to 
reduce the sensitivity to insulin in liver, 
muscle and fat tissue (25, 57, 128, 148, 149, 
176). The impairment of peripheral insulin 
sensitivity is largely confined to skeletal 
muscle (25, 148). Several studies have 
indicated that GH effects insulin action at 
the post-receptor level (25, 68,104,124,148, 
176,183). In addition, a decrease in glucose 
transporters has been noted during GH 
treatment (55, 200). GH increases lipolysis 
and elevates FFA levels in both normals (39, 
213) and GH-deficient adults (94, 147). It 
has therefore been suggested that some of 
the insulin-antagonistic effect of GH may be 
secondary to the increased availability of 
FFA which competes with glucose as an 
oxidative substrate (Randle's glucose-fatty 
acid cycle) (39, 168). The lipolytic effect of 
GH may involve an increase in the activity 
of hormone-sensitive lipase which catalyses 
the breakdown of s tored triglycerides into 
glycerol and fatty acids (47). Increased 
insulin levels are well-documented during 
GH treatment and may be secondary to the 
insulin-antagonistic effect of GH. However, 
the suggested insulinotropic effect of GH 
(151) may also contribute. 
Most of the data on insulin sensitivity 
in the GH-deficient state has been derived 
from early studies of animals with 
panhypopituitarism without adequate 
replacement treatment (6, 77). Hypo-
pituitary patients with GHD have 
traditionally been described as having 
increased insulin sensitivity. Young 
children with GHD are prone to fasting 
hypoglycemia (24, 60), possibly due to a 
decrease in hepatic glucose production, 
which is lower than glucose utilization (22). 
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Low glycogen stores (22), as well as 
decrease in the availability of ketone bodies 
(210), may contribute to this tendency 
towards fasting hypoglycemia. The 
availability of ketone bodies, in turn, 
depends upon an adequate supply of FFA 
and their synthesis into ketone bodies by 
the liver. 
In GH-deficient adults, fasting blood 
glucose concentrations are normal (131) and 
hypoglycemia is rare. However, prolonged 
fasting (four days) leads to decreased 
glucose levels compared with controls. 
Associated with this profound decrease in 
glucose is a higher than normal decrease in 
plasma insulin levels and concomitantly 
higher levels of FFA and ketone bodies 
(138). Hypoglycemic responsiveness to i.v. 
insulin is normal in GH-deficient adults, 
but the return of the blood glucose towards 
basal concentrations is delayed (59, 116 ). 
The cause of this delay may be a 
combination of decreased glycogen stores 
and the lack of GH which is of importance 
to the subsequent phase of glucose counter-
regulation after hypoglycemia (57). 
Under oral glucose loads, glucose 
tolerance was impaired, but the majority of 
the patients displayed hypoinsulinemia, in 
both GH-deficient adults (137) and children 
(124). A greater prevalence of abnormal 
glucose tolerance in GH-deficient adults has 
been reported (131). Fasting plasma insulin 
levels were normal in lean GH-deficient 
adults (131) but increased in obese GH-
deficient subjects compared with controls 
(186). However, information about insulin 
sensitivity in the untreated GH-deficient 
state has been limited. 
Secretory pattern and different 
modes of administration of GH 
The normal secretion pattern of GH is 
pulsatile, in both man and animals. In male 
rats, GH is secreted in a pulsatile fashion 
with low or undetectable levels between 
bursts, whereas, in female rats, secretion is 
more continuous with higher baseline levels 
than in males (50). Several differences in 
hepatic metabolism between male and 
female rats are explained by the sexually 
dimorphic secretory pattern of GH (50,141). 
The intermittent administration of GH to 
hypophysectomized rats has been more 
effective than continuous administration in 
terms of body weight gain, longitudinal 
bone growth (34, 85), increase in plasma 
IGF-1 level (129) and increase in IGF-1 
mRNA levels in various tissues (81, 130). 
The effect of different GH administration 
modes differs in some ways in the rat and 
in humans. 
In humans, the secretory pattern of GH 
does not differ between men and women to 
the same extent as in the rat. However, the 
mean 24-hour integrated GH secretion is 
higher in women than in men, as are the 
mean baseline GH levels (197, 209). During 
pregnancy, the GH secretory pattern 
becomes more continuous, with higher 
basal levels from the beginning of the 
second trimester (54). An increase in basal 
GH levels has also been observed during 
fasting (69) and in poorly controlled 
diabetes mellitus (9). Thus, changes in basal 
GH concentration may produce various 
metabolic adjustments during physiological 
and pathophysiological states. 
At present, rhGH is routinely 
administered as a daily s.c. injection in the 
evening. The serum GH profile following 
an evening s.c. GH injection differs from the 
physiological secretory pattern and can be 
characterised as an intermediate pattern 
between a pulsatile and a continuous 
pattern (32). Long-term replacement 
therapy with GH in GH-deficient subjects 
should theoretically mimic the complex 
physiological pattern of GH secretion. 
However, a physiological pattern of GH 
release is best simulated using the i.v route, 
which is difficult to achieve over prolonged 
periods. As an alternative to daily s.c. 
injections of GH, a sustained-release 
preparation has been proposed. The use of 
11 
such a GH preparation would presumably 
result in the continuous delivery of GH. 
In GH-deficient children, an 
improved long-term linear growth response 
is obtained when a fixed weekly GH dose is 
administered as daily s.c. injections 
compared with i.m. injections two or three 
times weekly (105). The higher plasma IGF-
1 level obtained with the former 
administration mode may contribute to the 
improved growth (33). Most studies 
designed to compare different modes of GH 
administration in GH-deficient adults have 
involved a treatment period of 24 hours 
only. In these studies, the increase in serum 
IGF-1 level was less pronounced following 
two i.v. GH pulses per day than following 
eight pulses or the continuous i.v. infusion. 
However, the effects on glucose 
homeostasis, lipid intermediates and 
IGFBP-3 were similar (97, 99). The 
metabolic effects of prolonged treatment 
with continuous GH administration in GH-
deficient adults have not been fully 
elucidated. 
Central nervous effects of GH 
During GH replacement therapy in 
GH-deficient adults, quality of life 
improves in terms of energy level and 
mood (133). In many patients, this 
improvement is dramatic. These beneficial 
effects of GH may be explained in part by 
the normalisation of body composition and 
the subsequent improvement in exercise 
capacity. However, it i s a lso possible that 
GH may have direct neuroendocrine effects 
on the CNS. In fact, neural actions by GH 
were first documented by Zamenhof in 
experiments on tadpoles in the early 1940s 
(211). A possible direct effect by GH on the 
CNS is supported by the finding that GH-
like material appears in the rat brain before 
its ontogenic appearance in the 
adenohypophysis (75). GH may thus play 
an important role in brain development, 
maturation and function. In studies of 
rodents and primates, it has been shown 
that the greatest content of immunoreactive 
GH is in the amygdala, hippocampus and 
hypothalamus. However, the concen­
trations are less than 1% of those in the 
anterior pituitary gland (74). The long-term 
presence of immunoreactive GH in the 
brain following hypophysectomy also 
suggests a central site of synthesis, as does 
the continuous release of immunoreactive 
GH from dispersed CNS cells from the rat 
grown in tissue culture (74). Moreover, the 
presence of GH mRNA in several areas of 
the brain supports the hypothesis of local 
synthesis of GH in the brain (61). It is also 
well established that GH stimulates 
neuronal and glial proliferation, myeli-
nation (154, 163) and RNA synthesis in the 
rat brain (14). 
Acromegalics have higher CSF GH 
levels compared with controls (123). 
However, the question of t he permeability 
of the blood-CSF barrier to GH has been 
controversial. The infusion of large 
amounts of h uman GH to rhesus monkeys 
was not followed by a parallel increase in 
CSF GH levels (11). On the other hand, 
intra-peritoneal injections of 
GH to rats resulted in an accumulation of 
radioactivity in several brain areas, thereby 
suggesting that GH crosses the blood-brain 
barrier in this species (196). It is also known 
that the systemic GH treatment of both 
normal and hypophysectomized rats 
influences the cerebral concentrations of 
monoamines. Monoamine changes were 
found as early as 15 min. after an injection 
of G H, thus suggesting that GH is r apidly 
taken up by brain tissue and quickly affects 
ongoing monoamine metabolism (195). GH 
also produced a rapid reduction in 
dopamine and noradrenaline concentra­
tions in the median eminence (8). The 
widespread presence of GH receptors in the 
CNS of several species has been reported 
(46, 125), whereas the information about 
GH receptors in the human brain has been 
scarce (46). 
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2. Aims of the studies 
• to investigate insulin sensitivity in untreated adult GH-deficient 
patients (Paper I) 
• to study fibrinogen concentrations and PAI-1 activity in adult 
GH-deficient patients (Papers II and HI) 
• to evaluate the effects of long-term treatment with GH on 
coagulation and fibrinolysis (Paper III) 
• to compare the metabolic effects of different GH administration 
modes (Paper IV) 
• to study the effects of GH on neurotransmitters and GH-
dependent factors in the CSF (Paper V) 
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3. Subjects Controls 
Patients 
All the patients in Papers I-V came 
from the catchment area of the Endocrine 
Unit which is the city of Göteborg and the 
western part of Sweden, comprising about 
one and a half million inhabitants. The total 
number of patients included in the different 
papers were 34 (23 men and 11 women). 
The characteristics of the patients are 
shown in Table 1. The 20 patients in Papers 
II and V were the same and 17 of these 
patients were included in Paper III. 
All the patients had been investigated 
as in-patients at the Endocrine Unit because 
of pituitary disorders. The majority of the 
patients had received surgical treatment for 
pituitary tumors and had multiple pituitary 
deficiencies. The patients were on stable 
replacement therapy with glucocorticoids 
(cortisone acetate, 12.5 mg twice a day), L-
thyroxine (0.10-0.15 mg/day) and sex 
hormones. Two patients in Paper I had had 
isolated GHD since childhood and three 
patients in Papers II, III and V had isolated 
GHD acquired in adult life. Two of these 
three patients were included in Paper IV. 
In Papers II, III and V, one patient was 
being treated with a calcium blocker, one 
with a ß-blocker and one with an 
angiotensin-converting enzyme inhibitor 
because of hypertension. Four men in Paper 
I, two men in Papers II and V and one man 
in Papers III and IV were being treated with 
bromocriptin. Four patients were current 
smokers, nine former smokers and 21 non-
smokers. 
Diagnosis of GHD 
GHD was defined as a peak serum 
GH concentration of below 5 mU/L during 
an i.v. insulin tolerance test (0.1 IU 
insulin/kg body weight) (73). All the 
patients showed symptoms of hypo­
glycemia and had a blood glucose of < 2.2 
mmol/L during the test. 
The healthy control subjects in Papers 
I and II were recruited by advertisements in 
the local newspaper. The criteria for being 
healthy, in addition to subjective well-
being, were a history of no hospital visits, 
no diabetes mellitus or hypertension and no 
medical treatment for any disease during 
the past two years. Of 255 answers in the 
40-60 year age group, 207 fulfilled the 
criteria for healthy controls. The controls 
were matched groupwise against the 
patients for age, sex and BMI. 
Ethical aspects 
All the studies were approved by the 
Ethics Committee at the Medical Faculty at 
Göteborg University and all the patients 
gave their informed consent. 
4. Methodological 
considerations 
In this section, some methods are 
described in greater detail than in the 
separate papers. For methods not addressed 
here, the reader is referred to Papers I-V. 
Glucose clamp technique 
To evaluate insulin sensitivity, a 
hyperinsulinemic, euglycemic clamp was 
performed, essentially as described by 
DeFronzo et al. (42). All the clamps were 
started in the morning after an overnight 
fast and were performed in the recumbent 
position. Patients waited with their normal 
hormone replacement and medical 
treatment until after the clamp had been 
performed. A catheter (Venflon, Ohmeda, 
Helsingborg, Sweden) was inserted into a 
cubital vein for glucose, insulin and 
potassium infusions. Blood samples were 
collected from a second catheter (Venflon) 
placed in a hand vein on the contralateral 
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arm. Both arms were warmed with electric 
heating pads in order to arterialize the 
venous blood and increase the blood flow 
for repeated blood sampling. The plasma 
insulin concentration was acutely increased 
by an infusion of a priming dose of insulin 
(Actrapid Human, Novo Nordisk, Copen­
hagen, Denmark) for 10 min. followed by a 
constant infusion of insulin dissolved in 
isotonic saline (40 mU/m^/min). The blood 
glucose concentration was kept constant 
close to 4.5 mmol/L by a variable 20% 
glucose infusion. Potassium chloride was 
infused at a rate of 7 mmol/h to prevent 
hypokalemia. Venous blood samples were 
drawn every 5 min to rapidly measure 
blood glucose with glucose test strips (BM-
test glycemie 1-44, Boehringer Mannheim, 
Germany) and a reflectometer (Reflolux II, 
Boehringer). Blood samples for subsequent 
chemical determinations were also drawn 
every 20 min during the clamps. The 
glucose levels in the results are from these 
samples and were measured using the 
glucose-6-phosphatase dehydrogenase 
technique (Beckman, Fullerton, CA, USA). 
The clamp was performed for two 
hours and the rate of insulin-mediated 
glucose uptake was calculated from the 
steady-state glucose infusion rate over the 
last 30 min. In these steady-state 
conditions, all the glucose infused is taken 
up by the peripheral tissues and thus serves 
as a measure of th e sensitivity of the tissue 
to the infused insulin. The glucose disposal 
rate during the clamp was expressed as 
both the amount of gl ucose infused per kg 
of body weight and per kg of LBM. It is 
important to express glucose uptake as a 
function of muscle mass since the skeletal 
muscles are the major determinants of 
glucose elimination in response to insulin. 
With the present plasma insulin levels 
(approximately 80-90 mU/L), an almost 
total suppression of hepatic glucose 
production is obtained during the clamps 
(58). 
Oral glucose tolerance test 
In order to evaluate the effect of G H 
treatment on glucose tolerance, an oral 
glucose tolerance test with 100 g of glucose 
dissolved in water was performed after an 
overnight fast. The test started at 8-9 am 
and venous blood samples were taken for 
glucose, insulin and C-peptide determi­
nations at 0, 30, 60, 90 and 120 min. 
Measurements of fibrinolytic 
variables and fibrinogen levels 
All the venous blood samples were 
drawn in the morning (8-9.30 am) after an 
overnight fast. To determine PAI-1 activity, 
t-PA antigen and fibrinogen, blood samples 
were drawn in 5-mL vacuum tubes 
containing 0.5 mL of 0.13 mol/L sodium 
citrate buffer (Venoject, Terumo Europe 
N.V., Leuven, Belgium). To determine PAI-
1 antigen, blood samples were drawn in 5-
mL vacuum tubes containing 0.5 mL of 0.45 
mol/L sodium citrate buffer (Biopool 
Stabilyte, Biopool, Umeå, Sweden). All the 
samples were immediately centrifuged at 
2000 g for 20 minutes. 
PAI-1 activity was measured using a 
Spectrolyse (pL) PAI kit (Biopool). The total 
coefficient of variation (CV) w as 12.0% (at 
11.9 U/mL) and 6.3% (at 43.6 U/mL). The 
method is an indirect two-stage enzymatic 
assay. In the first stage, a fixed amount of t-
PA is added to the plasma and allowed to 
react with the PAI-1 present. In the second 
stage, the residual t-PA activity catalyses 
the conversion of added plasminogen to 
plasmin, which in turn hydrolyses a 
chromogenic substrate. The amount of 
colour which develops is directly 
proportional to the amount of t-PA in the 
sample. As a result, the PAI-1 activity is 
equivalent to the inhibited amount of t- PA 
activity. 
PAI-1 antigen was measured using a 
Tint Elize PAI-1 kit (Biopool) which is a 
double antibody enzyme-linked immuno-
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sorbent assay (ELISA). The total CV was 
10.0% (at 7.3 ng/mL) and 6.5% (at 12.9 
ng/mL). 
t-PA antigen was measured using a 
Coaliza t-PA kit (Chromogenix, Mölndal, 
Sweden) which is a double antibody ELISA. 
The total CV was 9.5% (at 5.9 ng/mL) and 
8.1% (at 52.3 ng/mL). 
Fibrinogen was measured according 
to a syneresis method (152). The total CV 
was 4.1% (at 2.3 g/L). 
Measurements of GH, IGF-1 and 
IGFBP-3 in serum 
GH concentrations in serum were 
determined using a polyclonal immuno-
radiometric assay (IRMA) method (Pharma­
cia hGH RIA, Pharmacia, Uppsala, 
Sweden). The method had a detection limit 
of 0.3 mU/L (zero standard ± 2SD) and the 
total CV for the method was 5.3% (at 19.8 
mU/L) and 6.1% (at 84.9 mU/L). 
IGF-1 concentrations in serum were 
determined using a hydrochloric acid-
ethanol extraction radioimmunoassay (RIA) 
using authentic IGF-1 for labelling (Nichols 
Institute Diagnostic, San Juan Capistrano, 
CA, USA). The method had a detection 
limit of 13.5 |J.g/L with a total CV of 8% (at 
67 ng/L) and 6% (at 332 |ig/L). 
IGFBP-3 concentrations in serum were 
determined using an RIA (Nichols Insti­
tute). The method had a detection limit of 
0.06 mg/L with a total CV of 6.2% (at 2.05 
mg/L) and 5.7% (at 3.49 mg/L). 
Measurements of GH, IGF-1, IGFBP-
3, ß-endorphin immunoreactivity 
and monoamine metabolites in CSF 
The patients were put on a fast and 
confined to bed from midnight until the 
lumbar puncture was performed between 8 
and 9 am on the following day. Only 
hormone-replacement medication was 
taken in the morning. From the first mixed 
12 mL of CSF, 1-mL aliquots were frozen 
after centrifugation for the subsequent 
analysis of monoamine metabolites and 
IGFBP-3. The 15th to 25th mL of CSF were 
collected in 2-mL portions directly in 
prechilled polypropylene tubes (Cryotubes, 
Nunc, Roskilde, Denmark) containing 
peptidase inhibitors and frozen for the 
subsequent analysis of G H, IGF-1, opio id 
peptides and neuropeptides. Serum was 
collected simultaneously with the CSF and 
frozen in aliquots. 
GH levels in CSF were measured 
using an IRMA (BioMérieux, Lyon, France). 
The method had a detection limit of 1.3 
(J.U/L of GH and the intra-assay CV for the 
method was 3.5% (at 41.8 |iU/L) and 3.3% 
(at 79.0 nU/L). The assay was calibrated 
against the first international standard from 
the WHO (80:505; 2.6 U/mg). The linearity 
of the method was tested with a serial 
dilution procedure of CSF samples. The 
dilution curves were parallel to the 
standard curve, thus excluding unspecific 
cross-reactivity. 
IGF-I levels in CSF were determined 
using an RIA (Nichols Institute, Wijehen, 
the Netherlands). The method had a 
detection limit of 0.1 |ig/L and the intra-
assay CV for the method was 6.2% (at 0.28 
|i,g/L) and 5.2% (at 1.42 |ig/L). IGF-1 levels 
in CSF were measured after a C18 Sep-Pak 
column (Waters Assoc., Milford, MA, USA) 
extraction according to the manufacturer. 
IGFBP-3 levels in CSF were 
determined using an RIA (Nichols 
Institute). The method had a detection limit 
of 1.0 |ig/L and the intra-assay CV for the 
method was 3.3% (at 32.6 Hg/L) and 3.6% 
(at 54.7 |J.g/L). 
For ß-endorphin RIA, the anti-ß-
endorphin rabbit antibody N 1621 
(Amersham, Aylesbury, UK) was used. This 
antibody reacts 100% with human ß-
endorphin (ß-lipotropin 61-91), ß-
endorphin (1-5) + (16-31), ß-endorphin (6-
31) and ß-endorphin (18-31). It has 1-2% 
cross-reactivity with ß-lipotropin and < 1% 
cross-reactivity with g-endorphin, met- and 
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leu-enkephalin. The analyses were run 
directly on CSF. The method had a 
detection limit of 4.0 pmo/L and the intra-
assay CV for the method was 4.9% (at 40 
pmol/L). 
The dopamine metabolite HVA, the 
norepinephrine metabolite MHPG and the 
serotonin metabolite 5-HIAA in CSF were 
separated using a high-performance liquid 
chromatography (HPLC) system (Kontron 
Instruments, Zurich, Switzerland). The 
separation was carried out in a reverse-
phase mode on an Ultrasphere ODS column 
(Beckman Instruments, San Ramon, CA, 
USA). A Coulochem II electrochemical 
detector (ESA Inc., Bedford, MA, USA) with 
a conditioning cell (Model 5021) and a high-
sensitivity analytical cell (Model 5011) was 
used. The intra-assay CV for the methods 
was 4.2% (at 153.7 nmol/L) for HVA, 4.2% 
(at 25.5 nmol/L) for MHPG and 8.9% (at 
318.4 nmol/L) for 5-HIAA. 
Statistical methods 
Conventional statistical methods were 
used to calculate means, standard 
deviations and standard errors of the 
means. Correlations were sought by 
calculating Pearson's linear correlation 
coefficient (Papers I-IV) or Spearman's rank 
correlation coefficient (Paper V). 
In Paper I, differences between 
patients and controls were tested using 
Wilcoxon's test for paired differences and, 
in Paper II, using the exact permutation test 
(groupwise comparison). 
In Paper III, the intraindividual 
differences between the initial level and the 
levels at various time points of each 
variable were tested using Wilcoxon's test 
for paired differences. 
In Paper IV, a one-way analysis of 
variance (ANOVA) with the complete block 
design followed by the Student-Newman-
Keul multiple-range test was used to test 
the effects of GH treatment. 
In Paper V, comparisons between the 
treatment groups were performed using 
Fisher's permutation test. The intra­
individual differences between the initial 
level and the level after one month of 
treatment were analysed using the exact 
permutation test. 
Values of p < 0.05 were considered 
statistically significant. All the tests were 
two-sided. Descriptive values are given as 
the mean ± SEM unless otherwise specified. 
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5. Study design and results 
Paper I 
Study design: In a cross-sectional 
study, 15 GH-deficient adults were 
compared with healthy controls matched 
groupwise for sex, age and BMI. Insulin 
sensitivity was studied using the 
hyperinsulinemic euglycemic clamp tech­
nique. 
Results: Fasting blood glucose, 4.4 ± 
0.1 v 4.7 ± 0.2 mmol/L, and fasting plasma 
insulin, 9.5 ± 1.4 v 8.8 ± 1.1 mU/L, were 
similar in patients and controls respective­
ly. Blood glucose during the steady state of 
the clamp was also similar in patients and 
controls, 4.6 ± 0.1 v 4.9 ± 0.1 mmol/L, as 
were plasma insulin levels, 81 ± 4 v 93 ± 4 
mU/L. 
A decrease in glucose infusion rate 
(GIR) was seen during the clamp in the GH-
deficient patients, 3.9 ± 0.5 v 9.9 ± 0.7 
mg/kg body weight/min, as compared 
with controls (p = 0.001, Fig. 2a). Even if 
corrections were made for body fat, GIR in 
the patients was less than half that in 
controls, 5.8 ± 0.8 v 13.9 ± 0.9 mg/kg 
LBM/min (p<0.001, Fig. 2b). Since insu lin 
levels during the clamp tended to be lower 
in the patients (p = 0.1), the insulin sensi­
tivity index (GIR/plasma insulin) was 
evaluated and found to be about half that of 
controls (p<0.01, data not shown). 
Fasting FFA levels were lower in the 
patients, 444 ± 35 v 796 ± 94 |imol/L 
(p<0.01). At the end of the clamp, the FFA 
levels were lower in the patients, 53 ± 10 v 
121 ± 18 (imol/L, as compared with controls 
(p=0.001, Fig. 3). However, the decrease 
from the fasting level was similar in the two 
groups, 87% ± 2.6% and 84% ± 1.7% 
respectively. 
GIR per LBM among the patients 
correlated negatively with BMI (r = -0.56, 
p<0.05), f asting blood glucose (r = -0.58, 
p<0.05) and fasting plasma insulin 
concentrations (r = -0.60, p<0.05). 
15-1 
GHD GHD 
Fig. 2. GIR in adults with GHD compared with 
controls (C) (n=15). a) GIR per body weight b) GIR 
per LBM. *"p<0.001 v GHD 
# # #  
1 
£ 
« 
« 
1000 
750 
500-
250-
GHD Controls 
Fig. 3. Serum FFA concentrations before (lined) and 
at the end of th e clamps (filled) in patients with GHD 
compared with controls (n=15). "*p<0.001 v baseline 
levels, ##p<0.01 and ###p=0.001 v controls 
Paper II 
Study design: In a cross-sectional 
study, 20 GH-deficient adults were 
compared with healthy controls matched 
groupwise for sex, age and BMI. Fibrinogen 
levels, PAI-1 activity, metabolic and 
anthropometric data were studied 
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Results: WHR was higher in the 
patients than in the control subjects 
calculated from both sexes together and 
was most pronounced in female patients 
(Table 2-3). WHR was similar in male and 
female patients but differed between 
healthy men and women (p<0.001). 
The serum triglyceride concentration 
was higher and the blood glucose 
concentration lower in patients calculated 
from both sexes together, as well as in GH-
deficient men compared with their 
respective control group (Tables 2-3). 
Serum cholesterol (Table 2), fasting plasma 
insulin and blood pressure levels were 
similar in both patients and controls 
including both sexes. However, the 
cholesterol concentration was higher in GH-
deficient men (Table 3) and the systolic 
blood pressure was higher, 142 ± 21 v 123 ± 
9 mm HG (mean + SD), in GH-deficient 
women compared with their sex-matched 
controls (p<0.05). 
Table 2. Metabolic data, fibrinogen, PAI-1 activity and 
WHR in GH-deficient adults and healthy controls. 
Variable Patients 
(n=20) 
Controls 
(n=20) P 
fB-glucose, mmol/L 4.0±0.5 4.4+0.7 0.042 
Cholesterol, mmol/L 6.3+1.2 5.811.2 0.266 
Triglycerides, mmol/L 1.5±0.5 1.110.5 0.019 
Fibrinogen, g/L 3.2±0.7 2.4+0.6 0.0001 
PAI-1 activity, U/mL 13.2110.6 6.814.3 0.013 
WHR 0.9710.03 0.8710.09 0.0001 
The fibrinogen concentration was 
higher in patients than in controls (Table 2) 
irrespective of sex (Fig. 4). PAI-1 activity 
was also higher among the patients 
including both sexes than in the control 
subjects (Table 2), whereas the differences 
were less pronounced when men and 
women were studied separately (Table 3). 
PAI-1 activity among the patients 
correlated with the triglyceride 
concentration (r = 0.40, p<0.05), the insulin 
concentration (r = 0.51, p < 0.001) and the 
blood glucose concentration (r = 0.51, p < 
0.001). 
p=0.008 
p=0.001 
GHD 
fB=fasting blood. Values are mean ± SD. 
GHD C 
Women 
Fig. 4. Fibrinogen concentrations in adults with GHD 
compared with controls (C). n=10 in each of the four 
groups. Values are .mean 1 SD. 
Table 3. Metabolic data, PAI-1 activity and WHR for men and women separately in GH-deficient adults 
and healthy controls. 
Variable Men Women 
Patients Controls P Patients Controls P (n=10) (n=10) (n=10) (n=10) 
fB-glucose, mmol/L 4.110.5 4.810.6 0.01 3.810.4 3.910.5 0.707 
Cholesterol, mmol/L 6.710.7 5.010.6 0.0001 5.911.4 6.711.1 0.154 
Triglycerides, mmol/L 1.810.5 1.010.5 0.004 1.310.4 1.310.4 0.959 
PAI-1 activity, U/mL 15.4113.5 8.012.7 0.135 11.116.6 5.715.3 0.063 
WHR 0.9710.04 0.9310.05 0.062 0.97+0.02 0.8110.07 0.0001 
fB=fasting blood. Values are mean ± SD. 
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Paper III 
Study design: In an open prospective 
study, fibrinolysis and coagulation were 
studied in 17 of the patients in Paper II 
during two years of GH treatment. The 
impact of the contemporary changes in 
metabolic variables and body composition 
on coagulation and fibrinolysis was 
studied. The primary objective was to 
evaluate the changes after two years. 
Results - Fibrinolytic variables: PAI-
1 activity decreased after one and half years 
and after two years of GH treatment 
(p<0.05). PAI-1 antigen decreased after one 
and half years (p<0.01) and tended to 
decrease after two years (p = 0.06). t-PA 
antigen also decreased (p<0.05) (Fig. 1 in 
Paper III). 
The change in PAI-1 activity after two 
years of GH treatment was negatively 
correlated with PAI-1 activity at baseline, 
i.e. the decrease in PAI-1 activity was more 
pronounced in patients with initially high 
PAI-1 activity (r = -0.90, p<0.0001). Similar 
patterns were seen for PAI-1 antigen and t-
PA antigen (Figs. 2a-c in Paper III). 
a2-antiplasmin decreased from 119.3% 
± 5.0% to 102.1% ± 4.5% after two years of 
GH treatment (p<0.05). 
Coagulation variables: Fibrinogen 
concentrations tended to decrease from 3.3 
± 0.2 g/L to 3.0 ± 0.1 g/L after two years of 
GH treatment (p = 0.06). The change in 
fibrinogen was negatively correlated with 
fibrinogen at baseline, i.e. the decrease in 
fibrinogen was more pronounced in 
patients with initially high fibrinogen levels 
(r = -0.72, p<0.01). The decrease in fibrino­
gen was positively correlated with the 
decrease in WHR after two years of GH 
treatment (r = 0.52, p<0.05). 
Protein C decreased from 1.25 ± 0.06 
IU/mL to 1.11 ± 0.05 IU/mL after two years 
of GH treatment (p<0.05). 
Other fibrinolytic and coagulation 
variables measured in the study were 
unchanged after two years of GH 
treatment. The effects on all fibrinolytic 
and coagulation variables were similar in 
both sexes when studied separately. 
Metabolic data and body 
composition: Fasting plasma insulin 
concentrations increased from 8.3 ±1.0 
mU/L to 11.5 ± 1.6 mU/L (pcO.Ol), but 
blood glucose concentrations did not differ 
after two years of GH treatment. Serum 
triglycerides and total cholesterol 
concentrations were unaltered, while HDL 
cholesterol concentrations increased during 
the first year (p<0.05) but then levelled off 
(p = 0.09 after two years). Body fat de­
creased during the initial GH treatment but 
was unaltered after two years, while LBM 
increased from 53.5 ± 3.2 kg to 56.5 ± 3.2 kg 
(p<0.001) and WHR tended to decrease (p = 
0.06). 
Paper IV 
Study design: The effect of 
conventional evening s.c. injections was 
compared with a continuous s.c. infusion of 
GH (0.25 IU/kg body weight/week 
resulting in an average daily GH dose of 3.4 
± 0.2 IU) f or 14 days in nine GH-deficient 
men. All the patients received treatment 
with daily injections during the first 
treatment period and a continuous infusion 
during the second period. There was one 
month of wash-out between the treatment 
periods. 
Results: The two modes of ad­
ministration resulted in similar total 24-
hour urine GH excretion and similar 
morning serum GH concentrations. Daily 
injections and a continuous infusion of GH 
exerted similar effects in terms of body 
weight and body composition (Fig. 2 in 
Paper IV). 
Serum IGF-1 (Fig. 5) and IGFBP-3 
concentrations increased during both 
modes of treatment but more markedly 
during 14 days of continuous GH infusion. 
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Fig. 5. Effects of 14 days of one evening injection and 
continuous infusion of GH on serum IGF-1 in nine 
GH-deficient men. **p<0.01 v day 0 corresponding 
treatment, ##p<0.01 v the effect of treatment with 
one evening injection 
The molar IGF-1/IGFBP-3 ratio was 
similar for the two administration modes 
after 14 days (data not shown). IGFBP-1 
concentrations decreased during daily 
injections of GH (p<0.05). During the 
continuous infusion of GH, a marked 
decrease was noted, although it was not 
statistically significant. Serum GHBP 
concentrations were unaltered during both 
modes of GH treatment. 
Fasting blood glucose concentrations 
increased during treatment with daily GH 
injections, but they were not affected by the 
continuous infusion. The increase in fasting 
blood glucose concentrations was thus 
more marked after 14 days of daily GH 
injections compared with the continuous 
infusion (Fig. 6a). Fasting serum FFA 
concentrations increased during treatment 
with one daily injection of GH but did not 
change during the continuous infusion (Fig. 
6b). Fasting plasma insulin and C-peptide 
concentrations increased in a similar way 
during both modes of treatment. 
During the oral glucose tolerance test, 
blood glucose, plasma insulin and C-
peptide concentrations at 120 min. 
increased more markedly during daily 
injections of GH (p<0.01, p<0.05 and p<0.01 
respectively). The sum (values at 0, 30, 60, 
90 and 120 min.) of blood glucose increased 
more markedly during daily injections of 
GH (pcO.Ol), while the sum of plasma 
insulin and the sum of plasma C-peptide 
concentrations increased to a similar degree 
during the two modes of GH treatment. 
There were no differences between 
the two modes of treatment in terms of 
thyroid hormones or TSH concentrations. 
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Fig. 6. Effects of 14 days of one evening injection and continuous infusion of GH on a) blood glucose and b) 
serum FFA concentrations in nine GH-deficient men. **p<0.01 v day 0 corresponding treatment, #p<0.05 v the 
effect of treatment with one evening injection 
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Paper V 
Study design: In a randomized, 
placebo-controlled study, 10 patients in 
each of two groups were treated for one 
month with GH (0.25 IU/kg body 
weight/week) or placebo. Changes in 
neurotransmitters and GH-dependent 
factors in the CSF were studied. 
Results: In the GH-treated group, the 
mean CSF GH concentration increased 
tenfold compared with baseline (p = 0.002, 
Fig. 7). No correlation was found between 
the CSF and serum GH concentrations or 
between CSF GH concentrations and the 
GH dose given. 
The plasma IGF-1 concentration 
increased by 413.8% ± 106.2% (p = 0.002), 
while the CSF IGF-1 concentration 
increased by 47.1% ± 10.4% during GH 
treatment (p = 0.005, Fig. 8a). Similarly, CSF 
IGFBP-3 concentrations increased in the 
group allocated to GH (p = 0.002, Fig. 8b). 
The increase in CSF IGF-1 concentration 
correlated positively with the increase in 
300 
= 100 
CSF IGFBP-3 concentration (r = 0.81, 
p<0.05). However, no correlations were 
found between the increase in CSF and 
plasma IGF-1 or between the increase in 
CSF GH and CSF IGF-1 concentrations. 
CSF ß-endorphin immunoreactivity 
increased in all patients during GH 
treatment (p = 0.002, Fig. 9a), while the 
dopamine metabolite HVA decreased (p = 
0.02, Fig. 9b), as did VIP, 4.1 ± 0.6 pmol/L 
to 3.7 ± 0.4 pmol/L (p = 0.03). CSF 
concentrations of H VA correlated with the 
serotonin metabolite 5-HIAA both before (r 
= 0.91, pcO.OOl) and after GH treatment (r = 
0.89, pcO.OOl). A similar positive correlation 
was noted in the placebo-treated group 
(data not shown). 
CSF concentrations of enkephalin, 
dynorphin A, the norepinephrine 
metabolite MHPG, 5-HIAA, GABA, 
somatostatin and CRF were unchanged 
after one month of G H treatment. All the 
CSF variables were unchanged in the 
placebo treated group. 
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Fig. 7. Effects of GH (left) and placebo (right) on the CSF GH concentration in 10 GH-deficient adults. With the 
kind permission of Neuroendocrinology, Karger, Basel. 
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Fig. 8. Effects of GH (left top and bottom) and placebo (right top and bottom) on a) the CSF IGF-1 
concentration and b) the CSF IGFBP-3 concentration in 10 GH-deficient adults. With the kind permission of 
Neuroendocrinology, Karger, Basel. 
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Fig. 9. Effects of GH (left top and bottom) and placebo (right top and bottom) on a) the CSF ß-endorphin 
immunoreactivity and b) the CSF HVA concentration in 10 GH-deficient adults. With the kind permission of 
Neuroendocrinology, Karger, Basel. 
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6. General discussion 
Insulin resistance in GHD 
GHD has traditionally been described 
as a condition associated with increased 
insulin sensitivity. However, our results 
indicate that GH-deficient adults are 
insulin-resistant in peripheral tissues as 
measured with the hyperinsulinemic 
euglycemic clamp technique. GIR was less 
than half that of controls, both when 
calculated according to body weight and 
when corrected for body fat. The finding of 
insulin resistance in GH-deficient adults 
adds further metabolic abnormalities to the 
syndrome of adult GHD. A decrease in 
insulin sensitivity when estimated from i . V .  
glucose tolerance tests (156) or from insulin 
tolerance tests (71) supports the finding that 
GH-deficient adults are insulin-resistant. 
Furthermore, studies in recent years have 
suggested a greater prevalence of abnormal 
glucose tolerance in GH-deficient adults 
compared with controls (15,131). 
Insulin resistance can be defined as a 
situation in which a given concentration of 
insulin produces a less than normal 
biological response. It is a common 
condition and can be seen, for example, in 
non-insulin-dependent diabetes mellitus 
(type II), obesity and hypertension. The 
inter-relationship between insulin 
resistance and these conditions, as well as 
the exact mechanisms for insulin resistance, 
have not yet been fully clarified. 
In studies with a single insulin level 
during clamp, it is d ifficult to distinguish 
between insulin sensitivity and 
responsiveness (102). In our study, the 
insulin level was about 90 mU/L which 
elicits a near maximum insulin-stimulated 
glucose uptake in peripheral tissues. It is 
therefore likely that the insulin resistance 
seen in GH-deficient adults is mainly due to 
a decrease in responsiveness (104). It has 
recently been suggested that the reduction 
in glucose disposal is mainly due to a 
decrease in glucose storage rate and 
glycogen synthase activity in skeletal 
muscle (72). Low glycogen stores are 
supported by previous clinical studies of 
GH-deficient subjects (22, 187). Moreover, 
the basal glucose disposal and the hepatic 
glucose production, as well as the 
suppression of hepatic glucose production 
during hyperinsulinemic clamp, has been 
found to be similar in GH-deficient adults 
and controls (72). The sensitivity to insulin 
in the liver may therefore be normal in GH-
deficient adults. In addition to the liver and 
skeletal muscle, adipose tissue is a main 
target tissue for insulin. However, the 
degree to which the adipose tissue in these 
patients is sensitive to the action of insulin 
has not been fully elucidated. 
Abdominal obesity (II) and/or the 
decrease in LBM in GH-deficient patients 
may play an important role in insulin 
resistance. The well-known association 
between increased body fat and insulin 
resistance is stronger in the presence of a 
high WHR (64, 113). Other factors such as 
differences in muscle fibre morphology 
(reviewed in 41), skeletal muscle 
metabolism and decreased physical activity 
in GH-deficient patients (18) may be of 
importance. 
Since GH effects the insulin action at a 
post-receptor level (25, 68, 104 , 124, 148, 
176, 183), a post-receptor defect might 
consequently explain the insulin resistance 
in the GH-deficient state. Such a defect 
might be a reduction in glycogen synthase 
activity but also a change in function or the 
amount of glucose transporters (55, 200, 
201). Studies of the effect of GH on the 
numbers of insulin receptors and affinity 
have been inconsistent (25, 39, 68, 124,176, 
183). However, it is unlikely that such 
changes are a major cause of insulin 
resistance in GHD. 
A low serum IGF-1 concentration may 
contribute to insulin resistance (78, 79), 
since IGF-1 stimulates the glucose transport 
in the skeletal muscle in vitro (48, 127). 
Increased FFA levels due to abdominal 
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obesity appear to be an unlikely 
explanation of insulin resistance (86, 113, 
168) since we and others have observed low 
fasting FFA levels in these patients (4, 22, 
23), possibly due to decreased lipolysis in 
the absence of GH. 
No compensatory increase in fasting 
plasma insulin was observed in the patients 
(I-II, 72, 131). It is possible that an increase 
in insulin concentration is not required in 
the fasting situation. The fasting blood 
glucose level was also normal (I, 72,131) or 
even lower (II) in the patients compared 
with controls. In addition, low fasting FFA 
levels cause less competition with glucose 
as an oxidative fuel and may therefore lead 
to decreased insulin requirements (168). 
Moreover, the lack of GH may contribute to 
low fasting insulin concentrations since it 
has been suggested that GH is an 
insulinotropic hormone (151). 
It has been questioned whether the 
metabolic changes in GH-deficient adults 
are due to the lack of GH or are the result of 
imperfect Cortisol, thyroid and gonadal 
replacement therapy. Insulin resistance has 
been described in thyrotoxicosis (164, 194) 
and hypercortisolemia (134, 177). In 
addition, androgens (35, 64, 76, 146, 165) 
and female sex steroids influence insulin 
sensitivity (103, 119, 132, 165, 184). 
However, the data available on the change 
in insulin sensitivity induced by hormone 
replacement therapy in hypopituitarism is 
limited (3). It is unlikely that the 
replacement doses used in this study 
induce changes in insulin sensitivity of t he 
magnitude observed in these patients. 
Furthermore, insulin resistance was found 
both in patients with isolated GHD and in 
patients with multiple pituitary hormone 
deficiencies (104) and, in our study, the GIR 
was also low in the two patients with 
isolated GHD (1.7 and 6.8 mg/kg body 
weight/min respectively). 
The effect of long-term treatment with 
GH on insulin sensitivity in GH-deficient 
adults is not fully known. Six weeks of GH 
treatment in GH-deficient adults only 
induced a temporary decrease in insulin 
sensitivity which, after six months of 
treatment, was restored to baseline (58). An 
oral glucose tolerance test performed after 
three years of G H treatment disclosed no 
evidence of glucose intolerance (101). It 
remains to be seen whether insulin 
sensitivity further improves after longer 
GH treatment. 
Fibrinolysis and coagulation in GH-
deficient adults 
The elevation of fibrinogen levels and 
PAI-1 activity adds a new dimension to the 
risk factor profile for GH-deficient adults. 
These findings, together with dyslipidemia 
and abdominal obesity, link thrombo-
genesis with atherogenesis and might 
explain the increased risk of cardiovascular 
disease in hypopituitarism (53,131,178). 
In contrast to our findings, the 
fibrinogen levels did not differ between 
patients and controls in a previous study 
(131). However, in that study the fibrinogen 
levels were quite high in both patients and 
controls (about 3.5 and 3.2 g/L respec­
tively). Obesity has been associated with 
both increased fibrinogen levels and PAI-1 
activity (10, 49, 52, 108, 114, 144, 203). 
Although patients and controls were 
matched for BMI, we observed both higher 
fibrinogen levels and PAI-1 activity in the 
patients, suggesting that other factors in 
addition to obesity per se are of importance. 
Both the elevated fibrinogen levels and 
PAI-1 activity may be linked to the 
abdominal and visceral obesity, indicated 
by a high WHR in these patients (II). A 
higher WHR in GH-deficient adults has 
been found by others, in both sexes together 
(40, 185), as well as in men and women 
studied separately (15). In healthy women 
with a BMI similar to that of our female 
patients, the prevalence of a WHR of > 0.80 
was only 9% (112). In fact, such a high 
WHR as that observed among our patients 
was not seen even in grossly obese women 
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with a BMI of 36 kg/m^. In normal subjects, 
the average WHR is 0.70-0.80 in women 
(117) and 0.90-0.95 in men (118). 
Smoking has a powerful influence on 
fibrinogen levels (49, 108, 136, 208). 
However, the high fibrinogen levels among 
our patients cannot be explained by 
smoking habits since only one of these 
patients was a current smoker. Inte­
restingly, a lower prevalence of smoking 
has previously been reported in GH-
deficient adults compared with controls 
(180). High serum triglyceride concen­
trations have previously been noted in both 
GH-deficient men and women as compared 
with controls (180). Triglycerides correlated 
positively with PAI-1 activity in our 
patients as they did in healthy subjects (52, 
65, 83,115,144,198). 
Short-term studies lasting between 
two and four months have failed to show 
any effect by GH on t-PA antigen or PAI-1 
activity (98,160). In contrast, we observed a 
decrease in PAI-1 activity and PAI-1 
antigen after one and a half to two years of 
GH treatment. Furthermore, t-PA antigen, 
which forms a complex with and mainly 
measures PAI-1, decreased, thereby sup­
porting a true decrease in PAI-1 during GH 
treatment. PAI-1 is the major regulator of 
fibrinolytic activity in plasma and a 
decrease in PAI-1 is therefore assumed to 
result in increased fibrinolysis. 
The mechanism by which GH 
decreases PAI-1 activity, PAI-1 antigen and 
t-PA antigen is unclear. PAI-1 synthesis is 
influenced by a variety of factors including 
several growth factors (109,190,192). IGF-1 
has been shown to stimulate the synthesis 
of PAI-1 in vitro (160) but not during short-
term administration in vivo (160). The 
decrease in fibrinolytic variables might be 
secondary to the favourable changes in 
body composition and lipid metabolism (83, 
144, 198) following GH treatment (87) or a 
direct effect of GH itself. The changes in 
body composition in our study were similar 
to what has previously been observed in 
response to GH treatment (12, 16, 43, 100, 
185). In spite of increased insulin levels and 
unchanged triglyceride concentrations, the 
PAI-1 activity decreased which counter-
indicates any significant influence by these 
two factors on PAI-1 activity in GH-
deficient adults. It remains to be seen 
whether the decrease in PAI-1 activity, PAI-
1 antigen and t-PA antigen during long-
term GH treatment reduces the 
cardiovascular risk in GH-deficient adults. 
a2-antiplasmin is the rapid plasmin 
inhibitor which forms a complex with and 
inactivates plasmin. The observed decrease 
in a2-antiplasmin may therefore be the 
result of an increase in plasmin activity 
caused by the decrease in PAI-1. 
The fibrinogen levels were unaltered 
during the study period, although the levels 
tended to decrease after 24 months of GH 
treatment. In general, it has been difficult to 
influence fibrinogen levels during different 
treatments except for smoking cessation. 
GH is of importance for vitamin In­
dependent coagulation factors in the rat 
(150, 199). Despite an unaltered factor VII 
during GH treatment in the present study, 
an effect by GH on the biosynthesis of other 
vitamin K-dependent plasma coagulation 
factors in the liver is possible. The present 
study also confirms the previous 
observation of an unchanged factor VIII 
and von Willebrand factor antigen during 
prolonged GH treatment in GH-deficient 
adults (98). 
Similarities between GHD in adults 
and The Metabolic Syndrome 
The present study has extended our 
knowledge of the GHD syndrome in adults 
by adding insulin resistance and 
abnormalities in fibrinolysis and 
coagulation to the syndrome. Striking 
similarities thus exist between the so-called 
Metabolic Syndrome, also labelled Syn­
drome X or Primary Insulin Resistance 
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Syndrome, and the GHD syndrome in 
adults (13). 
The most central findings in both 
these syndromes are abdominal/visceral 
obesity and insulin resistance (169, 170, I). 
Other features common to both conditions 
are high triglyceride and low HDL 
cholesterol concentrations (169, 180), 
elevations of fibrinogen levels and PAI-1 
activity (170, II), an increased prevalence of 
hypertension (169, 180), premature athero­
sclerosis (131, 169) and increased mortality 
from cardiovascular diseases (169,178). The 
similarities between the two syndromes 
suggest that GH plays a role in the 
metabolic syndrome. 
Metabolic effects of GH related to 
mode of administration 
Continuous infusion and daily 
injections of GH (Paper IV) had similar 
effects on GH-dependent factors, but in 
some cases the magnitude of the effects 
differed. No carry-over effects were noted 
after one month of wash-out. It was 
therefore concluded that the effects of the 
first treatment period did not influence the 
effects of the second regimen. The urinary 
excretion of GH was similar during the two 
different modes of GH administration, 
indicating that similar amounts of GH 
reached the circulation. 
A diurnal variation in serum IGF-1 
concentration with the highest values in the 
morning has been observed in adult GH-
deficient patients receiving evening 
injections of GH (94). In control 
experiments, we observed a similar diurnal 
variation in serum IGF-1 concentration (88). 
Consequently, since all our measurements 
were made in the morning, we concluded 
that a continuous infusion of GH resulted in 
a significantly higher mean daily serum 
IGF-1 concentration. Similarly, frequent i . V .  
injections and the continuous admini­
stration of GH for 24 hours induced a 
greater increase in circulating IGF-1 
compared with a few injections a day (97). 
In the rat, liver GH receptors are 
upregulated by the continuous admini­
stration of GH, but not by repeated 
injections (130). A similar difference in the 
upregulation of GH receptors in the human 
liver is possible and might explain our 
finding of a more marked increase in IGF-1 
concentration during the continuous 
administration of GH. Since GHBP is 
believed to originate from the proteolytic 
cleavage of GH receptors, especially of 
hepatic origin, the lack of effects of GH 
treatment on GHBP concentrations in our 
study militates against this possibility. 
However, a continuous infusion of GH 
during a period of six months in GH-
deficient children resulted in a more 
marked increase in GHBP concentrations 
compared with daily injections (202). 
Like IGF-1, s erum IGFBP-3 concen­
trations increased to a greater degree 
during the continuous infusion of GH than 
during daily injections of GH. Previous 
short-term (24 h) administration of GH did 
not reveal any difference in IGFBP-3 
concentrations between intermittent and 
continuous administration (99, 120). How­
ever, in a four-week study, slightly higher 
IGF-1 and IGFBP-3 levels were noted 
during a continuous s.c. infusion of GH 
compared with daily single injections (121). 
The observed increase in fasting 
glucose and insulin levels is in agreement 
with previous findings during the GH 
treatment of GH-deficient adults (58, 94, 
185, III). T he higher fasting glucose and 
FFA levels during treatment with daily 
injections in the evening could be explained 
by a higher concentration of GH during the 
night and at dawn compared with the 
continuous infusion (94, 96). A higher GH 
concentration would cause an enhanced 
insulin-antagonistic effect (57) and 
increased lipolysis (166). The more 
impaired oral glucose tolerance after daily 
injections of GH may thus be explained by a 
higher serum GH concentration at dawn, 
since all the measurements were made in 
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the morning. Since IGF-1 has insulin-like 
effects (48, 63, 127), the more marked 
increase in serum IGF-1 during the 
continuous infusion of GH could 
theoretically counteract the deterioration in 
glucose homeostasis (78, 79). Recently, four 
weeks of daily single injections of GH were 
shown to result in higher daytime insulin 
levels and a tendency towards higher 
insulin levels after a morning oral glucose 
tolerance test compared with continuous 
infusion. In addition, the mean 24-hour 
levels of FFA tended to be slightly higher 
after daily injections of GH (121). 
A continuous s.c. infusion of G H for 
several weeks thus results in higher levels 
of IGF-1 and IGFBP-3 and less impaired 
glucose tolerance compared with daily 
injections. On the other hand, the 
continuous s.c. infusion of GH may have 
the disadvantages of a less physiological 
diurnal pattern of FFA (121), a more 
marked increase in lipoprotein (a) and a 
less pronounced decrease in LDL-
cholesterol compared with daily injections 
(159). Additional studies of the longer term 
metabolic effects of continuous GH delivery 
versus daily administration are necessary 
before a sustained-release preparation of 
GH can be routinely used. 
Central nervous effects of GH 
Previous findings of impaired quality 
of life in GH -deficient adults (18, 133) have 
been confirmed by more recent studies (27, 
44, 174, 182). Common complaints before 
GH treatment have related to tiredness, low 
energy, lack of concentration, memory 
difficulties and irritability (12, 44). 
Beneficial effects on certain cognitive 
functions, including memory, were 
reported at an early stage in the 
development of GH treatment in GH-
deficient adults (5). Additional studies have 
subsequently reported improvements in 
energy level, mood, emotional reactions, 
vitality and social isolation during GH 
treatment (12, 27,133,145). 
Recently, GH receptors have been 
found in many locations in the rodent and 
human brain (110, 111, 126, 143, 155). The 
highest density of GH receptors in the adult 
human brain have been noted in the 
choroid plexus, the hippocampus, the 
hypothalamus and the pituitary gland (110) 
(Fig. 10). While GH binding sites in the 
latter regions perform an obvious function 
in the regulation of pituitary GH secretion, 
the physiological relevance of GH binding 
sites in other brain regions is less clear. In 
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Fig. 10. Specific binding of [125 I]hGH to membranes from different parts of the human brain. The values are 
mean + SD (n=6). With the kind permission of Brain Research, Elsevier Science - NL, Amsterdam and the 
authors (110). 
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most brain tissues examined, the number of 
GH receptors was higher in women and 
there was an age-related decrease in the 
number of GH receptors irrespective of sex 
(111). 
The question of the permeability of 
the blood-CSF barrier to GH has been 
controversial (reviewed in 70). In our study, 
a mean ten-fold increase in GH in the CSF 
was observed during GH treatment, thus 
indicating that rhGH does pass the human 
blood-CSF barrier. The possible passage of 
GH over the blood-CSF barrier is also 
supported by the dose-related increase in 
the GH concentration in CSF reported in a 
recent study (28). The concentration of GH 
in the CSF is still low compared with serum 
(CSF:serum ratio about 5%). The increase in 
GH concentrations in the CSF was similar 
in patients with and without a damaged 
blood-CSF barrier. 
One possible mechanism behind the 
increase in GH in CSF is ultrafiltration, 
since most of the proteins in CSF are 
derived by this process. Alternative 
explanations are a GH receptor-mediated 
transport in the choroid plexus (110), a 
carrier-mediated transport system or a 
diffusion via the incomplete blood-brain 
barrier in the median eminence of 
hypothalamus (70). 
We observed that the mean increase 
in CSF IGF-1 concentrations was about 50%. 
IGF-1 may pass the blood-brain barrier in 
the rat (172), but it has not yet been 
demonstrated that a similar passage exists 
in humans (161). Previous clinical studies 
have indicated the existence of a blood-CSF 
barrier for IGFs and that IGF-1 present in 
the CSF is probably mainly derived from 
local CNS production (30). In line with 
these findings, we did not observe any 
correlation between the changes in plasma 
and CSF IGF-1 concentrations. The variant 
form of IGF-1 (truncated IGF-1) and IGF-1 
receptors have been found in a wide 
distribution throughout the adult human 
brain (2,31,188, reviewed in 20). IGF-1 may 
play an important role in brain maturatiôn, 
neural differentiation, survival (19), 
myelination (135) and energy metabolism 
(206). CSF IGFBP-3 concentrations also 
increased during GH treatment. It is likely 
that several of the IGFBPs which have been 
found in brain tissues modulate the action 
of IGF-1 (157). 
The fall in the CSF HVA concentration 
in response to GH treatment indicates that 
GH affects the dopamine turnover in the 
CNS. A similar decline in CSF HVA 
concentration was also noted during nine 
months of GH treatment (28). The results 
relating to CSF monoamine metabolites in 
depression and during treatment with 
antidepressants are equivocal (171, 175, 
212). Although GH-deficient adults often 
have symptoms similar to those seen in 
depressed patients, the mechanism behind 
these symptoms may not necessarily be the 
same. In animal studies, region-dependent 
changes in dopamine, noradrenaline, 
serotonin and 5-HIAA levels during GH 
treatment have previously been reported (8, 
195). As a result, region-dependent changes 
in brain monoamines may be present but 
not mirrored in the CSF during GH 
treatment in GH-deficient patients. 
A significant increase in CSF ß-
endorphin immunoreactivity was noted 
during GH treatment. Although the mean 
increase was limited (24.6% ± 7%), an 
increase was observed in all patients. The 
antiserum used was specific to the carboxy-
terminal half of the ß-endorphin peptide 
and had very low cross-reactivity with 
intact ß-lipotropin as well as with the 
amino-terminal parts of the ß-endorphin 
molecule. 
ß-endorphin is an endogenous opioid 
peptide consisting of 31 amino acid 
residues which, together with ACTH and 
MSH, is derived from the precursor pro­
opiomelanocortin (POMC). The post-
translational processing of POMC is 
regionally selective in the brain and other 
tissues, which means that different brain 
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regions contain different sets of POMC-
derived peptides. In addition to ß-
endorphin production by corticotrophic 
cells in the pituitary, ß-endorphin nerve 
cells can mainly be found in specific areas 
in the hypothalamus and the brain stem 
(107). ß-endorphin immunoreactivity in the 
CSF decreases markedly after hypo-
physectomy (191) and hypopituitary 
patients may thus have a decreased 
concentration of CSF ß-endorphin 
immunoreactivity. 
The mechanism behind the increase in 
CSF ß-endorphin immunoreactivity is 
unclear, but it may be a direct effect by GH 
on cells producing peptides derived from 
POMC or secondary to factors produced in 
the peripheral tissues that penetrate the 
blood-brain barrier. In contrast, no change 
in CSF ß-endorphin immunoreactivity was 
noted after nine months of G H treatment 
(28). The contrast in ß-endorphin results 
may reflect methodological differences. 
Recently, intracerebroventricular injections 
of GH to rats were found to increase the ß-
endorphin level in the pituitary and the 
levels of another opioid peptide in the 
spinal cord. (90). Previously, it has been 
shown that opioid peptides are involved in 
the stimulation of GH release (26, 45). 
Increased immunoreactivity of ß-endorphin 
in plasma after exercise is well-documented 
and several studies support a role for ß-
endorphin in the emotional well-being that 
follows exercise (82, 142). The possibility 
that the increase in CSF ß-endorphin 
immunoreactivity may be of importance for 
the improved psychological well-being 
noted during GH treatment in GH-deficient 
patients cannot be excluded. 
Taken together, this data shows that 
there are changes in CSF levels of GH, GH-
dependent factors and neurotransmitters 
during GH treatment in GH-deficient 
adults. Neuroendocrine mechanisms may 
very well be involved in the improvement 
in psychological well-being observed 
during GH treatment. 
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7. Summary and conclusions 
In the present study, metabolic and 
hemostatic factors associated with 
cardiovascular disease were evaluated in 
hypopituitary adults with untreated GHD. 
Furthermore, the effects of long-term GH 
treatment on hemostasis and the effects of 
GH on neurotransmitters and GH-
dependent factors in the CSF were studied. 
We also compared the metabolic effects of 
different GH administration modes. 
Insulin sensitivity, as assessed with 
the hyperinsulinemic euglycemic clamp 
technique, was markedly reduced in GH-
deficient subjects compared with matched 
controls, thus indicating that GH-deficient 
adults are insulin-resistant. Despite this, a 
normal fasting insulin level was found. GH-
deficient subjects had a similar or even 
lower fasting blood glucose level and a 
lower fasting FFA level compared with 
controls. 
The WHR, PAI-1 activity, fibrinogen 
and serum triglyceride levels were higher 
in GH-deficient patients compared with 
controls. 
After 18-24 months of GH treatment, 
PAI-1 activity, PAI-1 antigen and t-PA 
antigen decreased significantly. The rapid 
plasmin inhibitor, a2-antiplasmin, and the 
coagulation inhibitor, protein C, decreased. 
Fasting insulin levels increased, but blood 
glucose did not differ after two years of GH 
treatment. Favourable changes in body 
composition in terms of increased lean 
body mass were observed. It remains to be 
seen whether the decrease in fibrinolytic 
variables following GH treatment reduces 
the cardiovascular risk in these patients. 
In an administration study, daily s.c. 
injections in the evening and a continuous 
s.c. infusion of GH for 14 days had similar 
effects on several GH-dependent factors, 
but in some cases the magnitude of the 
effects differed. Serum IGF-1 and IGFBP-3 
levels increased to a higher degree during 
the continuous infusion of GH. Fasting FFA 
levels only increased during treatment with 
daily injections of GH. The fasting blood 
glucose level and an oral glucose tolerance 
test indicated more impaired glucose 
tolerance after daily injections of GH 
compared with continuous infusion. 
In another study, the mean CSF GH 
concentration increased tenfold compared 
with baseline after one month of GH 
treatment, thus indicating that GH does 
pass the human blood-CSF barrier. CSF 
IGF-1, CSF IGFBP-3 and CSF ß-endorphin 
immunoreactivity also increased during 
GH treatment, while the dopamine 
metabolite HVA and VIP decreased. The 
improved psychological well-being 
following GH treatment in GH-deficient 
adults might be related to neuroendocrine 
changes. 
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